The Second Affiliated Hospital of Xi'an Jiaotong Universi
Xi'an, Shaanxi, 710000, China
NCT Number: NCT07062120
This prospective, randomized, placebo-controlled study evaluated the synergistic effects of 30% salicylic acid (SA) chemical peels and topical 10% nicotinamide (NAM) in 56 patients with moderate-to-severe melasma. Participants were divided into four groups: placebo control, SA peels alone (every 2 weeks for 8 sessions), NAM cream alone (twice daily for 16 weeks), and combination therapy (SA+NAM). The investigators investigated the efficacy and safety of 30%SA chemical peeling combined with 10% NAM.
Looking for future studies?
Notify Me18 year–60 year
All sexes
Interventional
Not applicable
Xi'an, Shaanxi, 710000, China
Background:Melasma is a common skin disease manifested as brown patches with symmetrical distribution and irregular boundaries. Chemical peeling with salicylic acid (SA) is widely used in the treatment of melasma. Nicotinamide (NAM) is a common whitening agent and has a good effect in the treatment of melasma. In the present study, the investigators investigated the efficacy and safety of 30%SA chemical peeling combined with 10% NAM.
Methods: 56 moderate-to-severe melasma patients were enrolled and randomly assigned into the control group, SA group, NAM group, and SA+NAM group. SA treatment was given at an interval of 2 weeks for 8 treatment sessions (week 0, 2, 4, 6, 8, 10, 12, 14). NAM was applied twice a day for 16w. Photos, mMASI score, and skin indices (TEWL, skin hydration, melanin index, erythema index, red areas score, and UV spots score) were assessed at 0, 2, 4, 6, 8,10,12, and 14 weeks. Side effects, efficacy and satisfactory scores were recorded.
Limitations: Retrospective single-center design and small sample size.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The active niacinamide form of vitamin B3, NAM is routinely employed as a pigmentation-reducing agent in melasma treatment protocols
Salicylic acid, a superficial chemical peel, has been widely used in treating melasma. Breakthroughs in supramolecular design have addressed its irritancy profile through engineered SA complexes with improved water dispersibility
the same course of treatment in the same dosage form that does not contain salicylic acid
the same course of treatment in the same dosage form that does not contain nicotinamide
Time frame: From enrollment to week 16
The Primary outcomes were pre-defined as mMASI score and percent change in mMASI score, which was calculated as (mMASI at baseline-mMASI after treatment)/ mMASI at baseline × 100% and was graded as recovery (≥90%), obvious improvement (60-89%), improvement (20-59%), and no improvement (<20%).
Time frame: From enrollment to week 16
Use non-invasive skin analyzer to measure the melanin index on the patient's facial skin at each follow-up visit.
Time frame: From enrollment to week 16
Use non-invasive skin analyzer to measure the skin hydration on the patient's facial skin at each follow-up visit.
Time frame: From enrollment to week 16
Use non-invasive skin analyzer to measure the transepidermal water loss on the patient's facial skin at each follow-up visit.
Time frame: From enrollment to week 16
Use non-invasive skin analyzer to measure the erythema index on the patient's facial skin at each follow-up visit.
Time frame: From enrollment to week 16
Use VISIA to measure the UV spots on the patient's facial skin at each follow-up visit.
Time frame: week 16
Patient satisfaction was evaluated as very satisfied, satisfied, relatively satisfied and dissatisfied.
Second Affiliated Hospital of Xi'an Jiaotong University
Other
Efficacy and Safety of 30% Salicylic Acid and 10% Nicotinamide Combined Therapy in Melasma: A Randomized Placebo Controlled Study
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07727954
Hyperpigmentation, Melanosis
Tijuana, Estado de Baja California, Mexico
View Trial DetailsNCT07676994
Hyperpigmentation, Melanosis
Lahore, Pakistan
View Trial DetailsNCT07644871
Dark Spots, Hyperpigmentation
Irving, Texas, United States
View Trial DetailsNCT03877445
Hyperpigmentation, Melanosis
Nice, France
View Trial Details